fda to stop compounded semaglutide for weight loss | Blog FDA warns against compounded versions

Levine & Morley, 1981

*After 68 weeks, participants administering once-weekly semaglutide treatment experienced an average of 15% reduction in body weight

Most experiences of low energy stem from rapid weight loss, calorie restriction, or the body adapting to appetite suppression rather than from the medication itself

Differentiation and sustainable advantage shifts towards tolerability, outcomes beyond weight loss, and the quality of weight loss itself, including muscle and bone preservation and functional benefits

The abdomen is often preferred by patients and healthcare providers due to its accessibility, consistent subcutaneous fat layer, and ease of self-administration

Celebrate every win